13 results about "Prolyl Hydroxylases" patented technology

A method for treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional agents is described herein.

Disclosed herein is a method of modifying a T cell during T cell activation comprising contacting the T cell with an inhibitor of prolyl hydroxylase. Also disclosed is a method of producing a chimeric antigen receptor (CAR) or T cell receptor (TCR) T cell comprising (i) modifying the T cell during activation of the T cell by contacting the T cell with an inhibitor of prolyl hydroxylase, (i) introducing a CAR or TCR transgene into the modified T cell, and (iii) harvesting the CAR or TCR T cell. In particular, the inhibitor of prolyl hydroxylase is a small molecule prolyl hydroxylase inhibitor, such as 1, 4-DPCA. The harvested CAR or TCR T cells can be used for adoptive T cell immunotherapy of cancer.

The invention discloses a novel prolyl hydroxylase 2 and histone deacetylase 6 dual selective inhibitor as shown in a formula I as well as a preparation method and application thereof, and the prolyl hydroxylase 2 and histone deacetylase 6 dual selective inhibitor plays a role in relieving acute kidney injury caused by cis-platinum by simultaneously inhibiting the activity of prolyl hydroxylase (PHD2) and histone deacetylase 6 (HDAC6). The compound is expected to become a novel acute kidney injury treatment medicine.

Provided is a method for preparing a recombinant human collagen. The method comprises: constructing a genetically engineered bacterium which expresses a prolyl hydroxylase and a recombinant human collagen; culturing the genetically engineered bacterium and performing digestion treatment by means of pepsin to obtain a recombinant human collagen type I or type III. The prolyl hydroxylase comprises P4Ha2, P4Hb and vP4H, and by means of controlling the ratio of the copy numbers of the genes thereof, the recombinant human collagen and a natural human collagen are consistent in hydroxylation modification. Also provided is a large-scale production method for the recombinant human collagen. The prepared recombinant human collagen has completely the same sequence composition and length and substantially the same hydroxyproline content as the natural human collagen, and also has a stable full-length triple helix structure and biological activity without immunogenicity and potential risk of viruses.

Described herein are crystalline forms of small molecule inhibitor compounds (1) of Prolyl Hydroxylase Domain-containing Protein (PHD) and pharmaceutical compositions thereof, and methods of their use in the treatment of diseases or conditions that would benefit from treatment with inhibitors of Prolyl Hydroxylase Domain-containing Protein (PHD). (1)

Described herein are methods of treating inflammatory bowel disease using prolyl hydroxylase domain-containing protein (PHD) inhibitors and additional active agents.

This specification describes the crystalline form of compound (1), which is a low-molecular-weight prolyl hydroxylase domain-containing protein (PHD) inhibitor, its pharmaceutical composition, and its use in the treatment of diseases or conditions for which treatment with a prolyl hydroxylase domain-containing protein (PHD) inhibitor is beneficial. TIFF2026513705000031.tif32170

Disclosed are processes for preparing [(3-hydroxypyridine-2-carbonyl)amino]-alkanoic acids, derivatives, inter alia, 5-aryl substituted and 5-heteroaryl substituted [(3-hydroxypyridine-2-carbonyl]amino}acetic acids. Further disclosed are methods for making prodrugs of [(3-hydroxypyridine-2-carbonyl)-amino]acetic acids, for example, [(3-hydroxypyridine-2-carbonyl]amino}acetic acid esters and {[3-hydroxypyridine-2-carbonyl]amino}acetic acid amides. The disclosed compounds are useful as prolyl hydroxylase inhibitors or for treating conditions wherein prolyl hydroxylase inhibition is desired.

Disclosed herein are new therapeutic methods comprising administering compounds that can stabilize HIF and inhibit HIF prolyl hydroxylase (HIF-PH). In particular, methods described herein can be useful for treating / preventing a disease or condition in patients in need thereof, such as a patient having a viral infection such as a respiratory and / or pulmonary viral infection (e.g., an infection such as COVID-19 or a coronavirus infection). Methods described herein can also be useful for treating / preventing organ injury (e.g. organ injury that occurs concurrently or as a result of an infection). For example, methods described herein can be useful for treating or preventing acute lung injury, acute respiratory distress syndrome (ARDS), cardiovascular injury, injury to the liver, kidney diseases, and / or multi-organ failure.

The application belongs to the field of biological medicine, discloses a HIF prolyl hydroxylase 2 inhibitor as shown in formula (I), relates to a 4-quinazolinone compound and a preparation method thereof, further relates to a pharmaceutical composition containing the compound and purposes. The HIF prolyl hydroxylase mediated disease in the application is selected from the group of uses in anemia secondary to or associated with chronic kidney disease, anemia associated with or caused by chemotherapy or anemia associated with AIDS.

Described herein are PHD inhibitors and pharmaceutical compositions comprising said inhibitors. The subject compounds and compositions are useful for the treatment of anemia.

Crystalline form of small molecule prolyl hydroxylase domain-containing protein (PHD) inhibitors, their pharmaceutical compositions, and methods of use thereof in the treatment of anemia. TIFF2026513421000019.tif27170 Compound 1.

The present invention relates to the substance sebparin or a pharmaceutically acceptable salt thereof for use in the treatment of subjects with chronic kidney disease (CKD), which may also include anemia. This therapy may also be useful as a combination therapy with standard of care (SOC) therapies, such as erythropoiesis-stimulating agents (ESAs) or HIF prolyl hydroxylase inhibitors.